DK420385A - Antioestrogent laegemiddel til perkutan indgift - Google Patents

Antioestrogent laegemiddel til perkutan indgift Download PDF

Info

Publication number: DK420385A
Authority: DK; Denmark
Prior art keywords: pct; percutive; antioestrogent; administration; medicine
Prior art date: 1984-01-20

Application number

DK420385A

Other languages

English (en)

Other versions

DK420385D0 (da

DK155143C (da

DK155143B (da

Inventor

Pierre Mauvais-Jarvis

Frederique Kuttenn

Original Assignee

Mauvais Jarvis Pierre

Frederique Kuttenn

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-01-20

Filing date

1985-09-17

Publication date

1985-09-17

1985-09-17 Application filed by Mauvais Jarvis Pierre, Frederique Kuttenn filed Critical Mauvais Jarvis Pierre

1985-09-17 Publication of DK420385A publication Critical patent/DK420385A/da

1985-09-17 Publication of DK420385D0 publication Critical patent/DK420385D0/da

1989-02-20 Publication of DK155143B publication Critical patent/DK155143B/da

1989-07-03 Application granted granted Critical

1989-07-03 Publication of DK155143C publication Critical patent/DK155143C/da

Links

RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 2
210000000481 breast Anatomy 0.000 abstract 2
229940046836 anti-estrogen Drugs 0.000 abstract 1
230000001833 anti-estrogenic effect Effects 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000000328 estrogen antagonist Substances 0.000 abstract 1
-1 p-dimethylaminoethoxyphenyl Chemical group 0.000 abstract 1
229960003387 progesterone Drugs 0.000 abstract 1
239000000186 progesterone Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Dermatology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK420385A 1984-01-20 1985-09-17 Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet DK155143C (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
FR8400927		1984-01-20
FR8400927A FR2558373B1 (fr)	1984-01-20	1984-01-20	Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee
EP8400436		1984-12-21
PCT/EP1984/000436 WO1985003228A1 (fr)	1984-01-20	1984-12-21	Medicament antioestrogene pour administration percutanee

Publications (4)

Publication Number	Publication Date
DK420385A true DK420385A (da)	1985-09-17
DK420385D0 DK420385D0 (da)	1985-09-17
DK155143B DK155143B (da)	1989-02-20
DK155143C DK155143C (da)	1989-07-03

Family

ID=9300348

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK420385A DK155143C (da)	1984-01-20	1985-09-17	Antioestrogent laegemiddel til behandling af benigne og canceroese tilstande i brystet

Country Status (8)

Country	Link
US (1)	US4919937A (da)
EP (2)	EP0151326B1 (da)
JP (1)	JPH0667826B2 (da)
AT (1)	ATE73334T1 (da)
DE (1)	DE3485581D1 (da)
DK (1)	DK155143C (da)
FR (1)	FR2558373B1 (da)
WO (1)	WO1985003228A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8604528D0 (en) *	1986-02-24	1986-04-03	Ici Plc	Therapeutic agents
ES2077675T3 (es) *	1989-03-10	1995-12-01	Endorecherche Inc	Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos.
US5119827A (en) *	1990-09-05	1992-06-09	Board Of Regents, The University Of Texas System	Mechanisms of antiestrogen resistance in breast cancer
US5705185A (en) *	1991-09-25	1998-01-06	Beta Pharmaceuticals Co.	Transdermal delivery of estradiol and process for manufacturing said device
US5518734A (en) *	1991-09-25	1996-05-21	Beta Pharmaceuticals Co.	Transdermal delivery system for estradiol and process for manufacturing said device
GB9207437D0 (en) *	1992-04-03	1992-05-20	Orion Yhtymae Oy	Topical administration of toremifene and its metabolites
US5543150A (en) *	1993-09-15	1996-08-06	Columbia Laboratories, Inc.	Method of progesterone delivery and affect thereof
DE4407742C1 (de) *	1994-03-08	1995-06-22	Hexal Pharma Gmbh	Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat
DE59703511D1 (de) *	1996-03-29	2001-06-13	S W Patentverwaltungs Ges M B	Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der "cellulite"
RU2123838C1 (ru) *	1996-07-31	1998-12-27	Акционерное общество открытого типа "Нижфарм"	Состав для лечения гирсутизма
EP0943333A1 (de) *	1998-03-18	1999-09-22	S.W. Patentverwertungs GmbH	Medikament zur Prophylaxe und/oder Behandlung des Mammakarzinoms enthaltend einen Hemmer der Bildung von Oestrogenen
US20020086856A1 (en)	1998-03-18	2002-07-04	Alfred Schmidt	Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor
FI982733L (fi)	1998-12-17	2000-06-18	Orion Yhtymae Oyj	Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
US7863011B2 (en) *	2000-05-10	2011-01-04	Signe Biopharma, Inc.	Screening method for predicting susceptibility to breast cancer
MXPA02011092A (es)	2000-05-10	2004-08-19	David A Sirbasku	Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
US8119138B2 (en) *	2000-05-10	2012-02-21	Signe Biopharma Inc.	Anti-estrogen and immune modulator combinations for treating breast cancer
US20040092494A9 (en) *	2000-08-30	2004-05-13	Dudley Robert E.	Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) *	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
DE10054294A1 (de) *	2000-11-02	2002-05-16	Heinrich Wieland	Topische Behandlung bei der Mastalgie
EP1515748A4 (en) *	2001-11-14	2006-04-12	David A Sirbasku	ANTIESTROGEN AND IMMUNOMODULATOR COMBINATIONS FOR THE TREATMENT OF BREAST CANCER
JP2005513080A (ja)	2001-12-20	2005-05-12	フェムファーマ，インコーポレイテッド	薬物の膣送達
DE60327363D1 (de)	2002-12-18	2009-06-04	Besins Int Lab	Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen
MXPA05006526A (es) *	2002-12-18	2006-02-17	Besins Int Lab	Tratamiento de mastalgia con 4-hidroxi tamoxifen.
US9173836B2 (en)	2003-01-02	2015-11-03	FemmeParma Holding Company, Inc.	Pharmaceutical preparations for treatments of diseases and disorders of the breast
MXPA05007266A (es) *	2003-01-02	2006-01-17	Femmepharma Holding Co Inc	Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
ES2456958T3 (es)	2003-04-01	2014-04-24	Besins Healthcare Luxembourg Sarl	Formulaciones para prevención y tratamiento de cáncer de seno con 4-hidroxi tamoxifen
JP4682129B2 (ja) *	2003-06-09	2011-05-11	アセンドセラピュティクスインコーポレイテッド	４−ヒドロキシタモキシフェンによる過剰瘢痕化の治療及び予防
EP1550440A1 (en) *	2003-12-15	2005-07-06	Laboratoires Besins International	Use of 4-hydroxytamoxifen for the preparation of a medicament for the treatment of gynecomastia
PT1694319E (pt) *	2003-12-15	2008-10-24	Besins Int Lab	Utilização de 4-hidroxi-tamoxifeno na preparação de um medicamento para o tratamento da ginecomastia
US7968532B2 (en) *	2003-12-15	2011-06-28	Besins Healthcare Luxembourg	Treatment of gynecomastia with 4-hydroxy tamoxifen
US20050208139A1 (en) *	2004-03-22	2005-09-22	Ascend Therapeutics, Inc.	Chemically stable compositions of 4-hydroxy tamoxifen
US7507769B2 (en) *	2004-03-22	2009-03-24	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
PT1748770E (pt) *	2004-03-22	2008-07-16	Besins Int Lab	Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno
EP1579856A1 (en) *	2004-03-22	2005-09-28	Laboratoires Besins International	Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen
EP1647271A1 (en) *	2004-10-14	2006-04-19	Laboratoires Besins International	4-Hydroxy tamoxifen gel formulations
EA011295B1 (ru) *	2004-10-14	2009-02-27	Лаборатуар Безен Энтернасьональ	Рецептура геля с 4-гидрокситамоксифеном
US20070088012A1 (en) *	2005-04-08	2007-04-19	Woun Seo	Method of treating or preventing type-2 diabetes
ES3012497T3 (en)	2005-10-12	2025-04-09	Besins Healthcare Lu Sarl	Improved testosterone gel and method of use
KR100850910B1 (ko) *	2006-12-22	2008-08-07	삼성전자주식회사	블루투스 디바이스를 연결하기 위한 장치 및 방법
EP2104489A2 (en) *	2006-12-26	2009-09-30	FemmePharma Holding Company, Inc.	Topical administration of danazol
US20110003000A1 (en) *	2009-07-06	2011-01-06	Femmepharma Holding Company, Inc.	Transvaginal Delivery of Drugs
WO2018034945A1 (en)	2016-08-19	2018-02-22	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0002097B1 (en) *	1977-08-22	1981-08-05	Imperial Chemical Industries Plc	Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
DE3046719C2 (de) *	1980-12-11	1983-02-17	Klinge Pharma GmbH, 8000 München	1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FR2515041A1 (fr) *	1981-10-26	1983-04-29	Besins Jean	Medicament a base de progesterone pour le traitement des affections mammaires

1984
- 1984-01-20 FR FR8400927A patent/FR2558373B1/fr not_active Expired
- 1984-12-19 EP EP84201920A patent/EP0151326B1/fr not_active Expired
- 1984-12-21 EP EP85900469A patent/EP0169214B1/fr not_active Expired - Lifetime
- 1984-12-21 AT AT85900469T patent/ATE73334T1/de not_active IP Right Cessation
- 1984-12-21 US US06/777,786 patent/US4919937A/en not_active Expired - Lifetime
- 1984-12-21 WO PCT/EP1984/000436 patent/WO1985003228A1/fr not_active Ceased
- 1984-12-21 DE DE8585900469T patent/DE3485581D1/de not_active Expired - Lifetime
- 1984-12-21 JP JP60500495A patent/JPH0667826B2/ja not_active Expired - Fee Related
1985
- 1985-09-17 DK DK420385A patent/DK155143C/da active

Also Published As

Publication number	Publication date
DE3485581D1 (de)	1992-04-16
ATE73334T1 (de)	1992-03-15
EP0169214B1 (fr)	1992-03-11
EP0151326B1 (fr)	1989-07-12
EP0151326A1 (fr)	1985-08-14
DK420385D0 (da)	1985-09-17
JPH0667826B2 (ja)	1994-08-31
EP0169214A1 (fr)	1986-01-29
US4919937A (en)	1990-04-24
FR2558373B1 (fr)	1987-07-03
DK155143C (da)	1989-07-03
JPS61500914A (ja)	1986-05-08
WO1985003228A1 (fr)	1985-08-01
FR2558373A1 (fr)	1985-07-26
DK155143B (da)	1989-02-20

Publication	Publication Date	Title
DK420385D0 (da)	1985-09-17	Antioestrogent laegemiddel til perkutan indgift
ATE17079T1 (de)	1986-01-15	Praeparat zur behandlung von wunden der hautoberflaeche und verfahren zur herstellung des praeparats.
DE3684190D1 (de)	1992-04-16	Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE69132688D1 (de)	2001-09-20	Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE230985T1 (de)	2003-02-15	Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
ATE319474T1 (de)	2006-03-15	Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
IS3284A7 (is)	1988-05-22	Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
FR2441625A1 (fr)	1980-06-13	(d2-imidazolinyl-2 amino)-5 pyrimidines, procede pour les preparer, et medicaments qui en contiennent
JPS5756427A (en)	1982-04-05	Medicine containing 2-phenyl-1,2-benzisoselenazole- 3(2h)-one
DE3582439D1 (de)	1991-05-16	Mittel zur behandlung von herzerkrankungen.
SE9301290D0 (sv)	1993-04-20	Anvaendning av en somatostatinanalog
ATE55695T1 (de)	1990-09-15	Verwendung von defibrotid zur herstellung pharmazeutischer zusammensetzungen zur behandlung peripherer arteriopathien.
NO166939C (no)	1991-09-18	Analogifremgangsmaate for fremstilling av terapeutisk aktive carboxylsyrederivater.
US4678668A (en)	1987-07-07	Method of reducing soft tissue swelling and pain
ES478967A1 (es)	1980-08-16	Un procedimiento para preparar compuestos de acido 3-cefem-4-carboxilico disustituido en las posiciones 3 y 7.
FR2731907B1 (fr)	1997-06-20	Composition dermatologique et/ou cosmetique depigmentante et utilisation dans une methode cosmetique
JPS57122085A (en)	1982-07-29	Circulatory disease extirpenter and use
SE9801647D0 (sv)	1998-05-12	Therapeutic composition
FR2439194A1 (fr)	1980-05-16	Derives de la dibenzothiepine, leur procede de preparation et leur application therapeutique
ATE223721T1 (de)	2002-09-15	Edelfosin zur behandlung von hirntumoren
BR8008818A (pt)	1981-06-23	Peptidos farmacologicamente ativos e medicamentos contendo os mesmos
ES2006121A6 (es)	1989-04-01	Procedimiento para la preparacion de una composicion farmaceutica destinada al tratamiento de enfermedades cutaneas.
DE59108104D1 (de)	1996-09-26	Arzneimittel enthaltend cd14
PT85454A (de)	1987-08-01	Verwendung von 15-deoxyspergualin als arzneimittel
Hare et al.	1956	Acrodermatitis enteropathica